Trex Bio files for Nasdaq IPO; Eli Lilly eyes 19.9% stake
Trex Bio filed for a Nasdaq IPO under the ticker TRXB, with Eli Lilly planning to acquire up to 19.9% stake. The company's pipeline includes TRB-071 and TRB-051, with Eli Lilly partnering on the latter. Underwriters include J.P. Morgan, Evercore ISI, and others. The IPO aims to raise capital and establish a strategic partnership with Eli Lilly.
How this was made

The 30-second read
Why it matters
The strategic investment by Eli Lilly signals confidence in the pipeline, likely attracting institutional demand for the IPO.
Market read
First disclosure of a biotech IPO with a major pharma partner, creating a new tradable asset and sector interest.
What to watch
Potential regulatory hurdles for the CD30 programs and the timing of Phase 2a trials could affect valuation.
Background
Trex Bio is a biotech developing CD30 agonist antibodies; the IPO aims to fund its pipeline.
Market effects
Adds credibility to the biotech sector and may spur interest in similar early‑stage therapeutic companies.
Boosts US biotech IPO pipeline perception, especially for companies seeking strategic pharma partners.
Highlights cross‑border collaboration between US biotech and large pharma, relevant to global healthcare investors.
Counterpoint
The large stake by Eli Lilly could dilute existing shareholders and give the pharma giant outsized control.
Key entities
- companyTrex Bio
Biotech filing for Nasdaq IPO under ticker TRXB.
- companyEli Lilly
Potential strategic investor planning to acquire up to 19.9% of Trex Bio.


